|
1
|
Böttinger EP: TGF-beta in renal injury and
disease. Semin Nephrol. 27:309–320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ortiz A, Ucero AC and Egido J: Unravelling
fibrosis: two newcomers and an old foe. Nephrol Dial Transplant.
25:3492–3495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang S, Wilkes MC, Leof EB, et al:
Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal
interstitial fibrogenesis. Am J Physiol Renal Physiol. 298:142–149.
2010. View Article : Google Scholar
|
|
4
|
Yeh YC, Wei WC, Wang YK, et al:
Transforming growth factor-β1 induces Smad3-dependent β1 integrin
gene expression in epithelial-to-mesenchymal transition during
chronic tubulointerstitial fibrosis. Am J Pathol. 177:1743–1754.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zeng R, Han M, Luo Y, et al: Role of
Sema4C in TGF-beta1-induced mitogen-activated protein kinase
activation and epithelial-mesenchymal transition in renal tubular
epithelial cells. Nephrol Dial Transplant. 26:1149–1156. 2011.
View Article : Google Scholar :
|
|
6
|
Lee SB and Kalluri R: Mechanistic
connection between inflammation and fibrosis. Kidney Int Suppl.
119:S22–S26. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sankaran D, Bankovic-Calic N, Ogborn MR,
et al: Selective COX-2 inhibition markedly slows disease
progression and attenuates altered prostanoid production in Han:
SPRD-cy rats with inherited kidney disease. Am J Physiol Renal
Physiol. 293:821–830. 2007. View Article : Google Scholar
|
|
8
|
de Silva KI, Daud AN, Deng J, Jones SB,
Gamelli RL and Shankar R: Prostaglandin E2 mediates
growth arrest in NFS-60 cells by down-regulating interleukin-6
receptor expression. Biochem J. 370:315–321. 2003. View Article : Google Scholar
|
|
9
|
Yamamoto E, Izawa T, Juniantito V, et al:
Involvement of endogenous prostaglandin E2 in tubular
epithelial regeneration through inhibition of apoptosis and
epithelial-mesenchymal transition in cisplatin-induced rat renal
lesions. Histol Histopathol. 25:995–1007. 2010.PubMed/NCBI
|
|
10
|
Coleman RA, Smith WL and Narumiya S:
International Union of Pharmacology classification of prostanoid
receptors: properties, distribution, and structure of the receptors
and their subtypes. Pharmacol Rev. 46:205–229. 1994.PubMed/NCBI
|
|
11
|
Narumiya S, Sugimoto Y and Ushikubi F:
Prostanoid receptors: structures, properties, and functions.
Physiol Rev. 79:1193–1226. 1999.PubMed/NCBI
|
|
12
|
Hata AN and Breyer RM: Pharmacology and
signaling of prostaglandin receptors: multiple roles in
inflammation and immune modulation. Pharmacol Ther. 103:147–166.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsuoka Y, Furuyashiki T, Bito H, et al:
Impaired adrenocorticotropic hormone response to bacterial
endotoxin in mice deficient in prostaglandin E receptor EP1 and EP3
subtypes. Proc Natl Acad Sci USA. 100:4132–4137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsuoka Y, Furuyashiki T, Yamada K, et
al: Prostaglandin E receptor EP1 controls impulsive behavior under
stress. Proc Natl Acad Sci USA. 102:16066–16071. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mutoh M, Watanabe K, Kitamura T, et al:
Involvement of prostaglandin E receptor subtype EP(4) in colon
carcinogenesis. Cancer Res. 62:28–32. 2002.PubMed/NCBI
|
|
16
|
Moriyama T, Higashi T, Togashi K, et al:
Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive
mechanism of prostaglandins. Mol Pain. 1:32005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Makino H, Tanaka I, Mukoyama M, et al:
Prevention of diabetic nephropathy in rats by prostaglandin E
receptor EP1-selective antagonist. J Am Soc Nephrol. 13:1757–1765.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qian Q, Kassem KM, Beierwaltes WH and
Harding P: PGE2 causes mesangial cell hypertrophy and
decreases expression of cyclin D3. Nephron Physiol. 113:p7–p14.
2009. View Article : Google Scholar
|
|
19
|
Kennedy CR, Zhang Y, Brandon S, et al:
Salt-sensitive hypertension and reduced fertility in mice lacking
the prostaglandin EP2 receptor. Nat Med. 5:217–220. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takemoto M, Asker N, Gerhardt H, et al: A
new method for large scale isolation of kidney glomeruli from mice.
Am J Pathol. 161:799–805. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morino N, Mimura T, Hamasaki K, et al:
Matrix/integrin interaction activates the mitogen-activated protein
kinase, p44erk-1 and p42erk-2. J Biol Chem. 270:269–273. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li R, Mouillesseaux KP, Montoya D, et al:
Identification of prostaglandin E2 receptor subtype 2 as
a receptor activated by OxPAPC. Circ Res. 98:642–650. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Camacho M, Gerbolés E, Escudero JR, Antón
R, Garcia-Moll X and Vila L: Microsomal prostaglandin E synthase-1,
which is not coupled to a particular cyclooxygenase isoenzyme, is
essential for prostaglandin E(2) biosynthesis in vascular smooth
muscle cells. J Thromb Haemost. 5:1411–1419. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guan Y, Zhang Y, Wu J, et al:
Antihypertensive effects of selective prostaglandin E2
receptor subtype 1 targeting. J Clin Invest. 117:2496–2505. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vukicevic S, Simic P, Borovecki F, et al:
Role of EP2 and EP4 receptor-selective agonists of prostaglandin
E(2) in acute and chronic kidney failure. Kidney Int. 70:1099–1106.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
González AA, Céspedes C, Villanueva S,
Michea L and Vio CP: E Prostanoid-1 receptor regulates renal
medullary alphaENaC in rats infused with angiotensin II. Biochem
Biophys Res Commun. 389:372–377. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boor P, Ostendorf T and Floege J: Renal
fibrosis: novel insights into mechanisms and therapeutic targets.
Nat Rev Nephrol. 6:643–656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Q, Usinger W, Nichols B, et al:
Cooperative interaction of CTGF and TGF-β in animal models of
fibrotic disease. Fibrogenesis Tissue Repair. 4:42011. View Article : Google Scholar
|
|
29
|
Biswas S, Bhattacherjee P, Paterson CA,
Tilley SL and Koller BH: Ocular inflammatory responses in the EP2
and EP4 receptor knockout mice. Ocul Immunol Inflamm. 14:157–163.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yuhki K, Ueno A, Naraba H, et al:
Prostaglandin receptors EP2, EP3, and IP mediate exudate formation
in carrageenin-induced mouse pleurisy. J Pharmacol Exp Ther.
311:1218–1224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang K, Tarakji K, Zhou Z, et al:
Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases
monocyte chemoattractant protein-1 expression and neointimal
hyperplasia in the rabbit atherosclerotic balloon injury model. J
Cardiovasc Pharmacol. 45:61–67. 2005. View Article : Google Scholar
|
|
32
|
Wang M, Ihida-Stansbury K, Kothapalli D,
et al: Microsomal prostaglandin E2 synthase-1 modulates
the response to vascular injury. Circulation. 123:631–639. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang HM, Kim HS, Park KW, et al:
Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal
hyperplasia through inhibition of Akt signaling. Circulation.
110:301–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng HF, Wang CJ, Moeckel GW, et al:
Cyclooxygenase-2 inhibitor blocks expression of mediators of renal
injury in a model of diabetes and hypertension. Kidney Int.
62:929–939. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang JL, Cheng HF, Shappell S, et al: A
selective cyclooxygenase-2 inhibitor decreases proteinuria and
retards progressive renal injury in rats. Kidney Int. 57:2334–2342.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ramakrishnan M, Musa NL, Li J, Liu PT,
Pestell RG and Hershenson MB: Catalytic activation of extracellular
signal-regulated kinases induces cyclin D1 expression in primary
tracheal myocytes. Am J Respir Cell Mol Biol. 18:736–740. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chambard JC, Lefloch R, Pouysségur J and
Lenormand P: ERK implication in cell cycle regulation. Biochim
Biophys Acta. 1773:1299–1310. 2007. View Article : Google Scholar
|
|
38
|
Chen XL, Chen ZS, Ding Z, Dong C, Guo H
and Gong NQ: Antisense extracellular signal-regulated kinase-2 gene
therapy inhibits platelet-derived growth factor-induced
proliferation, migration and transforming growth factor-beta(1)
expression in vascular smooth muscle cells and attenuates
transplant vasculopathy. Transpl Int. 21:30–38. 2008.
|
|
39
|
Graf K, Xi XP, Yang D, Fleck E, Hsueh WA
and Law RE: Mitogen-activated protein kinase activation is involved
in platelet-derived growth factor-directed migration by vascular
smooth muscle cells. Hypertension. 29:334–339. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lavoie JN, Rivard N, L’Allemain G and
Pouyssegur J: A temporal and biochemical link between growth
factor-activated MAP kinases, cyclin D1 induction and cell cycle
entry. Prog Cell Cycle Res. 2:49–58. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Meloche S, Seuwen K, Pagès G and
Pouysségur J: Biphasic and synergistic activation of p44mapk (ERK1)
by growth factors: correlation between late phase activation and
mitogenicity. Mol Endocrinol. 6:845–854. 1992.PubMed/NCBI
|
